news

Immune processes offer insights into triple-negative breast cancer

Researchers have discovered the process that allows immune suppressor cells to develop, suggesting a potential new way to bolster immunotherapy treatment…

breast cancer

Cancer is crafty. To survive and thrive, tumours find a way of thwarting our body’s natural systems.

By looking at these systems, researchers at the University of Michigan Rogel Cancer Center have discovered that tumour cells reprogram metabolic pathways to gain control over a type of immune cell that allows cancer growth.

Myeloid-derived suppressor cells live in the tumour microenvironment and work to block cancer immunity. They also encourage a stem cell-like growth that’s linked to more aggressive cancer. Patients with a lot of these suppressor cells typically have worse outcomes. Essentially, their immune system isn’t strong enough to fight against the tumour.

 

Reserve your FREE place

 


Are you looking to optimise antibody leads in your drug discovery? Register for this webinar to find out how!

30 July 2025 | 10:00 AM BST | FREE Webinar

Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimise antibody leads in early drug discovery – and mitigate downstream risks later in development.

What You’ll Learn:

  • How to assess key developability risks early
  • How in silico modelling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
  • How micro-developability strategies are tailored for complex or novel formats

Don’t miss your chance to learn from real-world leaders

Register Now – It’s Free!

 

Further, when there are a large number of myeloid-derived suppressor cells, immunotherapy treatments tend to be ineffective because the immune T-cells are suppressed.

By looking at triple-negative breast cancer cells, researchers found that the metabolic process by which cells break down glucose also regulates the expression of a specific isoform of C/EBP-beta that in turn causes more suppressor cells to develop. The immune system can’t mount enough of an assault on the tumour cells, which translates to poor outcomes in triple-negative breast cancer patients.

“We don’t have many treatment options for triple-negative breast cancer. One of the immunological reasons may be that these tumours have a large number of myeloid suppressor cells. This could be an issue. We hope that by understanding the biology better, it may lead to new ways to help these patients,” says Dr Weiping Zou, the Charles B. de Nancrede Professor of Surgery, Pathology, Immunology and Biology at the University of Michigan.

Essentially, it’s a cascade: The process glycolysis initiates things. It targets a molecular mechanism called LAP, a specific isoform of C/EBP-beta, which then controls the expression of G-CSF and GM-CSF, small proteins made by tumour cells, which support myeloid suppressor cells and result in immunosuppression.

Researchers examined this relationship in triple-negative breast cancer cell lines and in mouse models. They then looked at patient tumour samples to assess how the metabolic pathway, the number of suppressor cells and immune signatures linked with patient survival. Looking at samples from 250 triple-negative breast cancer patients, they found that when the metabolic pathway for glycolysis was enriched, so were the immune suppressor cells – and this linked with worse overall survival. In contrast, tumours with a high T-cell signature exhibited fewer of these suppressor cells and the patients had better outcomes.

Leave a Reply

Your email address will not be published. Required fields are marked *